The use of plasma metabolomics to predict the risk of amyotrophic lateral sclerosis

Takeaway

  • Metabolic profiles of blood samples years before amyotrophic lateral sclerosis (ALS) diagnosis were unable to reliably separate pre-symptomatic ALS cases from controls.

Why this matters

  • This could suggest that ALS is not preceded by a long prodromal phase as seen in other neurodegenerative disorders.